The Biognosys Group announced advancements across its integrated multiomics portfolio at the 74th Annual American Society for Mass Spectrometry (ASMS) conference. The updates introduce next-generation software, sample preparation, enrichment, and separation technologies for proteomics and metabolomics to enhance sensitivity, reproducibility, and throughput.
Next-Gen Software Benchmarks
The group launched Spectronaut 21 (DIA) and SpectroMine 6 (DDA) software, setting new benchmarks by increasing identification rates by approximately 10% more protein groups across a cohort of 65 proteomics datasets and roughly 11% more peptides across a cohort of 27 immunopeptidomics datasets. Powered by advanced directDIA and next-generation AI-driven post-translational modification (PTM) prediction, the platforms improve computational efficiency, delivering up to 15% faster processing of directDIA data.
"Spectronaut is our preferred DIA analysis software due to its high performance and user-friendly interface, which makes analyzing our complex and multiplex DIA datasets both easy and reliable," shares Yansheng Liu, PhD, Associate Professor at Yale University School of Medicine.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
"Spectronaut is an excellent addition to our informatics capabilities, especially for its thorough analysis of large-scale DIA phosphopeptide data and advanced modification localization algorithm," adds Prof. Dr. Matthias Mann, Director of the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry.
Optimized Proteomics Workflows
In sample preparation, the group introduced the iST-S workflow, an optimized extension of the PreOmics iST workflow that enables robust, reproducible proteomic depth from sub-microgram sample inputs down to 0.5 micrograms.
For blood-based studies, an optimized P2 single-particle enrichment workflow expands deep proteome coverage to serum and heparin plasma matrices, demonstrating up to a 4-fold increase in protein group identifications compared to neat measurements.
Additionally, the group presented an optimized end-to-end tissue workflow that combines PreOmics BeatBox and iST, paired with Bruker’s PepSep Advanced columns on the nanoElute 2, timsTOF, and Spectronaut to enable scalable, high-throughput FFPE proteomics from minimal inputs without requiring deparaffinization.
Partnerships and Targeted Testing
To expand targeted testing, Biognosys partnered with SISCAPA Assay Technologies to qualify ultrasensitive targeted protein assays for clinical research. This includes combining Biognosys' proteomics expertise with SISCAPA's peptide-antibody enrichment for high-sensitivity absolute protein quantification, such as UBE3A in human cerebrospinal fluid (CSF) to monitor Angelman syndrome.
Hybrid Metabolomics Preview
Finally, Bruker and Biocrates previewed a novel hybrid metabolomics workflow on the timsMetabo platform using Biocrates' MxQuant kits. The workflow unifies quantitative targeted metabolomics with untargeted discovery inside a single integrated PASEF experiment, eliminating the need to double sample consumption or instrumentation time.
"By combining quantitative metabolomics with discovery on timsMetabo, we are unifying targeted and untargeted workflows in a way that produces data-rich and future-proof digital metabolome archives," summarizes Matthew Lewis, PhD, Bruker’s Vice President of Metabolomics and Lipidomics.
This article is based on a press release issued by the Biognosys Group.
